These new liraglutide results are encouraging and provide further support that this class of drugs is doing something interesting in the context of Parkinsons
Organization and evolution of the human growth hormone receptor gene 5-flanking region
Here is a direct comparison of each agents impact on fat loss, trial data, timelines, and practical considerations for individuals seeking weight loss
Participants received diet (500 kcal deficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg, n =9095), placebo ( n =98) or open-label orlistat (120 mg 3, n =95)
This supports reduced fatigue, improved stamina, and faster recovery in patients with vitamin deficiency or illness-related weakness